The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of mutant IDH (mIDH) inhibition on DNA hydroxymethylation, tumor cell function, and tumor immune microenvironment (TIME) in resected mIDH1 lower-grade glioma (LGG).
 
Min Lu
Employment - Agios
Stock and Other Ownership Interests - Agios; Gilead Sciences; Johnson & Johnson; Pfizer
Patents, Royalties, Other Intellectual Property - Agios
 
Timothy Francis Cloughesy
Stock and Other Ownership Interests - Chimerix; Katmai Pharmaceuticals; Notable Labs
Consulting or Advisory Role - Abbvie; Agios; Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; DelMar Pharmaceuticals; DNAtrix; Global Coalition for Adaptive Research; GW Pharmaceuticals; Inovio Pharmaceuticals; Karyopharm Therapeutics; Katmai Pharmaceuticals; KIYATEC; Merck; Novartis; Pascal Biosciences; Pfizer; QED Therapeutics; Roche/Genentech; Sapience Therapeutics; Tocagen; VBI Vaccines; VBL Therapeutics
Patents, Royalties, Other Intellectual Property - U.S. Provisional Application No.: 62/819,322 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Filing Date: March 15, 2019 Inventor(s): David A. Nathanson et al. FH Reference No.: UCH-17760 (32246-17760) Your Reference No.: [UCLA 2019-630-1] US
Other Relationship - Global Coalition for Adaptive Research
 
Patrick Y. Wen
Consulting or Advisory Role - Agios; AstraZeneca; Bayer; Blue Earth Diagnostics; Deciphera; deciphera; ElevateBio; Immunomic Therapeutics; Imvax; Integral Health; Karyopharm Therapeutics; KIYATEC; Puma Biotechnology; QED Therapeutics; Taiho Pharmaceutical; Taiho Pharmaceutical; Tocagen; Vascular Biogenics; VBI Vaccines; Voyager Therapeutics
Speakers' Bureau - Merck; Prime Oncology
Research Funding - Abbvie (Inst); Agios (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Celgene (Inst); Kazia Therapeutics (Inst); Lilly (Inst); MediciNova (Inst); Merck (Inst); Novartis (Inst); Oncoceutics (Inst); Puma Biotechnology (Inst); Vascular Biogenics (Inst); VBI Vaccines (Inst)
 
Ania Tassinari
Employment - Agios
Stock and Other Ownership Interests - Agios
 
Sung Choe
Employment - Agios
Stock and Other Ownership Interests - Agios
Patents, Royalties, Other Intellectual Property - Patents derived from my work at Agios
Travel, Accommodations, Expenses - Agios
 
Dongwei Zhu
Employment - Agios; Alkermes; Intellia Therapeutics (I); Wave Life Sciences (I)
Stock and Other Ownership Interests - Agios; Bayer; CVS; Intellia Therapeutics (I); Novartis (I); Novo Nordisk; Pfizer; Roche (I); Sanofi (I); Wave Life Sciences (I)
 
Islam Hassan
Employment - Agios
Stock and Other Ownership Interests - Agios
 
Lori Steelman
Employment - Agios
Stock and Other Ownership Interests - Infinity Pharmaceuticals
 
Shuchi Sumant Pandya
Employment - Agios
Stock and Other Ownership Interests - Agios
 
Bin Wu
Employment - Agios
Stock and Other Ownership Interests - Agios
Patents, Royalties, Other Intellectual Property - Agios
 
Ingo K. Mellinghoff
Honoraria - Roche
Consulting or Advisory Role - Agios; Black Diamond Therapeutics; Debiopharm Group; Puma Biotechnology; Voyager Therapeutics
Research Funding - Amgen; General Electric; Lilly
Travel, Accommodations, Expenses - Agios; AstraZeneca; Puma Biotechnology; Roche; Voyager Therapeutics